OR WAIT null SECS
© 2022 MJH Life Sciences and Pharmaceutical Technology. All rights reserved.
© 2022 MJH Life Sciences™ and Pharmaceutical Technology. All rights reserved.
More technologies and treatments are emerging for COVID-19—along with new variants.
Partnerships formed during the COVID-19 pandemic have provided a platform for change in assay development and transfers.
An annual survey on inspections and audits has revealed opportunities to use more flexible approaches to optimize processes.
August 24, 2022
Anthony Fauci announced that he plans to step down as Director of the National Institute of Allergy and Infectious Diseases in December 2022.
August 15, 2022
The United Kingdom has approved Moderna’s bivalent COVID-19 vaccine, which targets the original variant and Omicron.
August 12, 2022
Moderna and the European Commission have amended their agreement to convert contractually agreed doses of Moderna’s COVID-19 vaccine to the company’s Omicron-containing bivalent vaccines for supply in 2022.
August 01, 2022
The United States has agreed to purchase 66 million doses of Moderna’s bivalent COVID-19 booster candidate for $1.74 billion.
July 18, 2022
FDA has granted an Emergency Use Authorization to Novavax’s COVID-19 vaccine.
July 02, 2022
As a result of the disruptions caused by the COVID-19 pandemic, global arbitration has adapted to a ‘new normal’.
June 30, 2022
Following the recommendation of an independent vaccine panel, FDA is advising vaccine manufacturers to include an Omicron BA.4 and BA.5 component to their booster doses.
June 27, 2022
The Sanofi-GSK vaccine is the first candidate to demonstrate efficacy in a placebo-controlled trial with a high-Omicron environment.
June 21, 2022
The agency will review laboratory study and CMC data on the bivalent vaccine that targets two strains of the SARS-CoV-2 virus.
June 17, 2022
FDA has issued an Emergency Use Authorization for the Moderna and Pfizer-BioNTech COVID-19 vaccines in children as young as six months old.